mindbio therapeutics

The Canadian-based biopharma company MindBio Therapeutics Corp. CSE: MBIO obtained regulatory approval for a series of clinical trials in women's health using its proprietary LSD drug, MB22001. The company said it is the only one in the world with regulatory approvals of the...

MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6) have started pre-screening for participant entry into phase 2 LSD-microdosing clinical trials. The clinical trials are a for take home use of MindBio's LSD-microdosing treatment. The initial phase 2a open label trial will assess the...

Blackhawk Growth Corp. (OTCMKTS: BLRZF), an investment holding company focused on acquiring and developing high-growth companies in the health, cannabis and psychedelics sectors in the US and Canada, announced it intends to complete a spin-out transaction of its wholly-owned subsidiaries MindBio...

Holding company Blackhawk Growth Corp.(OTC: BLRZF)'s subsidiary company MindBio Therapeutics Pty Ltd shared the positive data gathered from its Phase 1 clinical trials microdosing LSD formulation in 80 healthy participants. A practical summary of the outcomes collected at this stage: microdoses...

Blackhawk Growth Corp. (OTC: BLRZF), the investment holding company focused on health, psychedelics, cannabis and cannabidiol’s industries opportunities, announced its next annual general meeting is set for September 30, 2022, and likewise shared its latest corporate decisions.  ...

Mindbio Therapeutics, a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp. (OTC: BLRZF), together with research collaborators at the University of Auckland, have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (...

Mindbio Therapeutics, a company of the Blackhawk Growth Corp. (OTCPK: BLRZF) announced the completion of the world’s largest Phase 1 clinical trial for LSD microdosing. The randomized, double-blind placebo-controlled clinical trial lasted 12 months and included 80 healthy participants....